Table 1.
Baseline Characteristics of Sarcoid Patients with Mild-to-Moderate Disease, and Treated with Placebo or POF
| Placebo | POF | Placebo | POF | ||
|---|---|---|---|---|---|
| AgeII | 44 ± 2 | 49 ± 3 | Dyspnea Scale | ||
| 0 | 3 | 4 | |||
| Gender | 1 | 6 | 5 | ||
| Male | 5 | 3 | 2 | 4 | 3 |
| Female | 9 | 10 | 3 | 1 | 1 |
| 4 | 0 | 0 | |||
| Ethnicity | |||||
| Caucasian | 8 | 2 | PFTsII (means) | ||
| African-American** | 6 | 11 | FEV1 % Predicted | 85 ± 6 | 90 ± 7 |
| FVC % Predicted | 86 ± 4 | 89 ± 6 | |||
| Smoking Status | TLC % Predicted | 86 ± 4 | 91 ± 5 | ||
| Never | 9 | 9 | DLCO % Predicted** | 91 ± 5 | 78 ± 6 |
| Ex-Smoker | 5 | 4 | |||
| Current Smoker | 0 | 0 | Arterial PaO2II(mean) (mmHg) and [kPa] |
84 ± 2 [11.17] |
80 ± 3 [10.64] |
| Initial Mean Prednisone | |||||
| Radiographic Stage++ | DoseII (mg/day) | 16 ± 3 | 15 ± 4 | ||
| 0 (Normal) | 1 | 2 | |||
| I (Hilar LN) | 2 | 2 | Mean SACEII,**(U/L) | 24 ± 3 | 44 ± 6 |
| II (Hilar LN & Infiltrates) | 3 | 4 | |||
| Mean BAL | |||||
| III (Infiltrates) | 7 | 4 | macrophages^ | 75.8% | 71.1% |
| IV (Fibrocystic Disease) | 1 | 1 | |||
II
Values represent means ± SEM.
**
P < 0.05 as determined by either a two-tailed Fisher’s exact test or Student’s t-test.
++
All patients had a history of radiographic stages equal to or greater than 1; LN = lymph node.
^
The BALF data was derived from 13 placebo - and 10 POF - treated subjects, respectively